Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542070 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 687
- Enrollment target
NCT04542070 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 687 participants.
The verdict
NCT04542070, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 687 participants
- Enrollment target
Study Summary
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
Interventions
- DRUG Cabotegravir Tablets
- DRUG Rilpivirine Tablets
- DRUG Cabotegravir Injectable Suspension (CAB LA)
- DRUG Rilpivirine Injectable Suspension (RPV LA)
- DRUG BIKTARVY Tablets (BIK)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 687 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2023-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542070
The ClinicalTrials.gov registry entry for NCT04542070 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 687 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cabotegravir Tablets is the first listed.
NCT04542070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542070 about?
NCT04542070 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed". This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
What is the current status of trial NCT04542070?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 687 participants. The study started on 2020-11-09. Estimated completion is 2023-04-17.
What interventions are being tested in trial NCT04542070?
The interventions under investigation include: Cabotegravir Tablets (DRUG), Rilpivirine Tablets (DRUG), Cabotegravir Injectable Suspension (CAB LA) (DRUG), Rilpivirine Injectable Suspension (RPV LA) (DRUG), BIKTARVY Tablets (BIK) (DRUG).
Who is sponsoring clinical trial NCT04542070?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.